Provided by Tiger Trade Technology Pte. Ltd.

INDIVIOR PLC

36.87
-0.9100-2.41%
Post-market: 36.890.0200+0.05%19:59 EDT
Volume:2.50M
Turnover:92.77M
Market Cap:4.35B
PE:13.33
High:38.52
Open:37.68
Low:36.70
Close:37.78
52wk High:42.81
52wk Low:22.22
Shares:118.00M
Float Shares:109.00M
Volume Ratio:1.35
T/O Rate:2.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.77
EPS(LYR):1.64
ROE:12.20%
ROA:26.40%
PB:-20.92
PE(LYR):22.48

Loading ...

Indivior Pharmaceuticals, Inc : Stifel Raises Target Price to $52 From $42

THOMSON REUTERS
·
May 06

A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Q1 Beat, Raised 2026 Guidance And Buyback News

Simply Wall St.
·
May 05

Sector Update: Health Care

MT Newswires Live
·
May 04

Indivior Pharmaceuticals Enters $175 Million Accelerated Share Repurchase Agreement

MT Newswires Live
·
May 04

Indivior announces $175M accelerated share repurchase program

TIPRANKS
·
May 04

Indivior Announces $175 Million Accelerated Share Repurchase

THOMSON REUTERS
·
May 04

Indivior Earnings Call Highlights SUBLOCADE-Fueled Momentum

TIPRANKS
·
May 02

Indivior Pharmaceuticals, Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
Apr 30

Indivior Pharmaceuticals Q1 revenue rises 19%, beats estimates

Reuters
·
Apr 30

Indivior Pharmaceuticals Q1 Revenue USD 317 Million Vs. IBES Estimate USD 272.8 Million

Reuters
·
Apr 30

Indivior Q1 GAAP net income rises 89% to $89 million; revenue climbs 19% to $317 million

Reuters
·
Apr 30

Indivior Q1 Adj. EPS $0.96 Beats $0.66 Estimate, Sales $317.000M Beat $272.840M Estimate

Benzinga Earnings
·
Apr 30

Indivior Pharmaceuticals, Inc - Revises FY 2026 Net Revenue Guidance to $1,215 Mln-$1,285 Mln

THOMSON REUTERS
·
Apr 30

Indivior Pharmaceuticals, Inc - Revises FY 2026 Adj Ebitda Guidance to $620 Mln-$660 Mln

THOMSON REUTERS
·
Apr 30

Indivior Pharmaceuticals, Inc - Revises FY 2026 Sublocade Net Revenue Guidance to $950 Mln-$990 Mln

THOMSON REUTERS
·
Apr 30

Addex Therapeutics publishes 2025 annual report

Reuters
·
Apr 30

Addex FY25 net loss widens to CHF 6.7 million; cash falls to CHF 1.6 million

Reuters
·
Apr 30

Evaluating Indivior Pharmaceuticals (NasdaqGS:INDV) After New ASAM 2026 Data On Sublocade Effectiveness

Simply Wall St.
·
Apr 28

Indivior study links Sublocade-based OUD remission to better quality-of-life outcomes

Reuters
·
Apr 24

Does Indivior (INDV) Survey Support For Long-Acting Buprenorphine Strengthen Its Criminal Justice Strategy?

Simply Wall St.
·
Apr 19